WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H471035
CAS#: 70018-51-8
Description: Quazinone, is a phosphodiesterase 3 (PDE3) inhibitor and novel cardiotonic agent with vasodilating properties.
Hodoodo Cat#: H471035
Name: Quazinone
CAS#: 70018-51-8
Chemical Formula: C11H10ClN3O
Exact Mass: 235.05
Molecular Weight: 235.671
Elemental Analysis: C, 56.06; H, 4.28; Cl, 15.04; N, 17.83; O, 6.79
Synonym: Quazinone; Ro 13-6438
IUPAC/Chemical Name: (3R)-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one
InChi Key: BHZFZYLBVSWUMT-ZCFIWIBFSA-N
InChi Code: InChI=1S/C11H10ClN3O/c1-6-10(16)14-11-13-9-4-2-3-8(12)7(9)5-15(6)11/h2-4,6H,5H2,1H3,(H,13,14,16)/t6-/m1/s1
SMILES Code: O=C1NC2=NC3=C(C(Cl)=CC=C3)CN2[C@@H]1C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO and Ethanol
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO and Ethanol
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 235.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Lau, H. Y. A., et al.: Inflamm. Res., 54, S5-S6 (2005); Rickards, K. J., et al.: J. Vet. Pharmacol. Ther., 26, 277 (2003)
2. Osinski, M.T., and Schrör, K. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: Role of protein kinase A in vascular smooth muscle cell mitogenesis. Biochem. Pharmacol. 60(3), 381-387 (2000).
3. Taher, A., Meyer, M., Stief, C.G., et al. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J. Urol. 15(1), 32-35 (1997).
4. Eigenmann, R., Gerold, M., and Holck, M. Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties. J. Cardiovasc. Pharmacol. 6(3), 511-519 (1984)